MIRA Pharma (MIRA) Short-Term Debt to Equity

MIRA Pharmaceuticals is focused on the long-term advancement of synthetic cannabinoid analogs to combat depression and pain syndromes. The company is developing safe plant-based treatments that eliminate the risk of addiction, a critical demand in modern medicine. The current debt-to-equity ratio stands at 0.00, and the price chart on the GURU.Markets platform clearly illustrates the asset's price action.

This ratio measures the proportion of short-term liabilities relative to equity, allowing investors to assess liquidity risk and the probability of default through the ratio of current debts to net assets. By analyzing the trend of short-term loans relative to equity, one can confirm the financial stability of MIRA Pharmaceuticals (MIRA), which is critical for a pre-revenue biotech company with high preclinical research expenditures.